Title:
A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve
Phase:
I/II
Contact:
Silvia Koerner / Study Nurse
Email-Address:
silvia.koerner@med.uni-heidelberg.de
Clinical Investigator:
Prof. Dr. Jessica Hassel
Registration:
Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe
NCT03787602
EudraCT-Number:
Siehe EU klinisches Studienregister
2020-002820-35